There are currently 999 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
NCT05996627
Recruiting
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the n... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Chronic Graft Versus Host Disease
Register for Updates
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590
Recruiting
This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm). A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/22/2025
Locations: Tampa General Hospital / University of South Florida, Tampa, Florida
Conditions: Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Register for Updates
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT03495427
Recruiting
This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer: (VANDAAM)" that had high risk Decipher test results (Decipher score \>0.45). Patients with a high genomic classifier (GC) score at diagnosis will be approached for formal consenting for PSMA-PET imaging at 2 years post treatment.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Prostate Cancer, Recurrent Prostate Cancer
Register for Updates
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
NCT04741997
Recruiting
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Register for Updates
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT05325632
Recruiting
The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: HER2-positive Breast Cancer
Register for Updates
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430
Recruiting
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Register for Updates
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
NCT05558124
Recruiting
The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia
Register for Updates
Outreach Core Activities
NCT05832177
Recruiting
The Ponce Health Sciences University-Moffitt Cancer Center (PSHU-MCC) U54 Outreach Core (OC) goal is to increase community cancer awareness, community engagement (CE) and participation in cancer health disparities research and outreach in Hispanic/Latino communities through the following: Aim 1: To develop, deliver, and disseminate cancer education and outreach activities to Hispanic/Latino community members to reduce cancer health disparities. Aim 2: To enhance capacity for mutually beneficia... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Cancer Education, Spanish Language Cancer Education
Register for Updates
Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
NCT06235281
Recruiting
This is an open label, single arm, single-center, pilot study of concurrent phototherapy and POTELIGEO (mogamulizumab-kpkc) in early-stage mycosis fungoides.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Mycosis Fungoides
Register for Updates
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196
Recruiting
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1 (Dose Escalation) will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered orally. Approximately 50 participants may be enrolled in Phase 1 of the study. Phase 1b (Dose Expansion... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
Register for Updates
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
NCT06511882
Recruiting
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia
Register for Updates
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
NCT06855212
Recruiting
The purpose of the study is to determine if cemiplimab in combination with cetuximab given before their surgery are beneficial and safe in participants with head and neck squamous cell carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates